2+ T cells (Table 1) H-2u mice were injected i p with 5×106 apop

2+ T cells (Table 1). H-2u mice were injected i.p with 5×106 apoptotic Vβ8.2+ T cells or Vβ8.2− T cells. 7–10 days later CD4+ T cells were isolated from the spleen and stimulated in vitro with 40 μg peptide B5 for 72 h, CD4+ T cells were then harvested and 4–5×106 cells transferred

ABC294640 research buy i.p into naïve WT or CD8−/− recipients. Recipient mice were challenged with MBPAc1-9/CFA/PTx and EAE was monitored. Table 1 demonstrates that WT recipient mice that received CD4+ T cells from donors that had been immunized with Vβ8.2+ apoptotic T cells and not Vβ8.2− apoptotic T cells were protected from EAE. However, CD8-deficient recipients of CD4+ T cells derived from mice immunized with either apoptotic Vβ8.2+ or Vβ8.2− T cells were not protected. These results indicate that TCR B5-reactive CD4+ Treg function in a CD8-dependent fashion to control EAE in H-2u mice 3, 15–19, 30. Next we determined whether DC that have captured apoptotic Vβ8.2+ T cells could prime B5-reactive CD4+

Treg in vivo. To do this, DC were either left unpulsed, pulsed with peptide B5 (10 μg/mL) or Vβ8.2+ Ap-T cells (2–3×106). DC populations were selected on CD11c find more expression, LPS-treated (1 μg/mL) and 1×106 DC were injected i.p. After 5 days spleens were harvested, and antigen recall responses of the splenocyte population were analyzed using IFN-γ ELISPOT assays. Figure 4A shows a significantly higher (p<0.05) number of splenocytes secreting IFN-γ on recall response to TCR peptide B5 (10 μg/mL) was associated with the transfer of DC pulsed with Vβ8.2+ Ap-T cells or TCR peptide B5, compared with DC only transfer. Furthermore, we determined the subtype of DC that was most efficient for the priming of B5-reactive CD4+ Treg. T-helper 1 and 2 responses have been shown to be associated with CD8α+ or CD8α− DC, respectively 27, 28. Previously we demonstrated in the H-2u mouse that effective CD4+ Treg-mediated regulation is dependent on the generation of a Th-1-type response to TCR peptide B5 3, 29. We sought to determine whether CD8α+ or CD8α− DC could ADAMTS5 effectively prime CD4+ Treg responses.

DC were isolated on CD11c expression from the spleen of naïve mice, and FACS sorted into CD8αhigh and CD8αlow populations. Sorted DC were then pulsed with peptide B5 (10 μg/mL), and injected i.p into B10.PL mice (0.5×106 cells/mouse). After 10 days, draining LN cells were collected and recall responses to antigen B5 determined in a proliferation assay. Figure 4B shows that injection of CD8αhigh DC was associated with a significantly higher (p=0.0140) recall response to peptide B5 compared with those injected with CD8αlow DC. Thus, the ability to effectively prime CD4+ Treg resides within the CD8αhigh DC population. The data above indicate that DC pulsed either with TCR peptide B5 or apoptotic Vβ8.2+ T cells can stimulate CD4+ Treg both in vitro and in vivo. We have recently demonstrated that DC pulsed with apoptotic Vβ8.2+ T cells protect against EAE 24.

Comments are closed.